An official website of the United States government
Government Funding Lapse Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.
The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.
Updates regarding government operating status and resumption of normal operations can be found at opm.gov.
A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed or Refractory Solid Tumors
Trial Status: active
This is an open-label, multicenter, Phase 1/2 study evaluating the safety and efficacy of
CTX131™ in subjects with relapsed or refractory solid tumors.
Inclusion Criteria
Age ≥18 years.
Unresectable or metastatic, relapsed/refractory, clear cell renal cell carcinoma, cervical carcinoma, pancreatic adenocarcinoma, esophageal carcinoma, and malignant pleural mesothelioma.
Eastern Cooperative Oncology Group performance status 0 or 1.
Adequate renal, liver, cardiac and pulmonary organ function.
Female subjects of childbearing potential and male subjects must agree to use acceptable method(s) of contraception from enrollment through at least 12 months after CTX131 infusion. Key
Exclusion Criteria
Prior treatment with anti-CD70 targeting agents
History of certain central nervous system (CNS), cardiac or pulmonary conditions.
Presence of uncontrolled bacterial, viral, or fungal infection.
Active HIV, hepatitis B virus or hepatitis C virus infection.
Primary immunodeficiency disorder or active autoimmune disease requiring steroids and/or other immunosuppressive therapy.
Women who are pregnant or breastfeeding.
Additional locations may be listed on ClinicalTrials.gov for NCT05795595.
Locations matching your search criteria
United States
California
Duarte
City of Hope Comprehensive Cancer Center
Status: Active
Name Not Available
Palo Alto
Stanford Cancer Institute Palo Alto
Status: Active
Name Not Available
North Carolina
Durham
Duke University Medical Center
Status: Active
Name Not Available
An open-label, multi-center Phase 1/2 study of CTX131 in subjects with
relapsed/refractory solid tumors. CTX131 is an is allogeneic CD70- directed chimeric
antigen receptor (CAR) T cell immunotherapy comprised of allogeneic T cells that are
genetically modified ex vivo using CRISPR-Cas9 (clustered regularly interspaced short
